ATE162308T1 - Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendung - Google Patents
Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendungInfo
- Publication number
- ATE162308T1 ATE162308T1 AT88907519T AT88907519T ATE162308T1 AT E162308 T1 ATE162308 T1 AT E162308T1 AT 88907519 T AT88907519 T AT 88907519T AT 88907519 T AT88907519 T AT 88907519T AT E162308 T1 ATE162308 T1 AT E162308T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- monoclonal antibodies
- binding specificity
- day
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7368587A | 1987-07-15 | 1987-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE162308T1 true ATE162308T1 (de) | 1998-01-15 |
Family
ID=22115160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT88907519T ATE162308T1 (de) | 1987-07-15 | 1988-06-07 | Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US5512443A (de) |
EP (1) | EP0394277B1 (de) |
JP (1) | JP3095752B2 (de) |
AT (1) | ATE162308T1 (de) |
CA (1) | CA1339980C (de) |
DE (1) | DE3856108T2 (de) |
IL (1) | IL86809A (de) |
WO (1) | WO1989000692A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756065A (en) * | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
US6051225A (en) * | 1988-10-19 | 2000-04-18 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
US5993813A (en) * | 1988-10-19 | 1999-11-30 | The Dow Chemical Company | Family of high affinity, modified antibodies for cancer treatment |
US6641999B1 (en) | 1988-10-19 | 2003-11-04 | The Dow Chemical Company | Probing method for identifying antibodies specific for selected antigens |
CA2008213A1 (en) * | 1989-02-21 | 1990-08-21 | David A. Hilborn | Method of fragmenting certain monoclonal antibodies |
US6495137B1 (en) | 1990-04-19 | 2002-12-17 | The Dow Chemical Company | Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains |
US5976531A (en) * | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
WO1993012231A1 (en) * | 1991-12-13 | 1993-06-24 | Dow Chemical (Australia) Limited | Composite antibodies of human subgroup iv light chain capable of binding to tag-72 |
ATE187494T1 (de) | 1992-12-11 | 1999-12-15 | Dow Chemical Co | Multivalente einkettige antikörper |
JP2001501596A (ja) | 1996-08-27 | 2001-02-06 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | バイオコンジュゲートおよび生物学的活性剤の送達 |
US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
US6045774A (en) * | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
US5919135A (en) * | 1997-02-28 | 1999-07-06 | Lemelson; Jerome | System and method for treating cellular disorders in a living being |
US6418338B1 (en) * | 1998-02-06 | 2002-07-09 | Phylatron Ltd. | Method for detecting and surgically removing lymphoid tissue involved in tumor progression |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6897044B1 (en) * | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
US6696620B2 (en) * | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
US6852510B2 (en) * | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
EP1297168A2 (de) * | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expressionsvektoren |
US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
EA007388B1 (ru) * | 2001-01-29 | 2006-10-27 | Идек Фармасьютикалз Корпорейшн | Модифицированные антитела и способы применения |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
WO2002079255A1 (en) * | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
CA2490659C (en) | 2002-06-28 | 2014-08-19 | Syed V. S. Kashmiri | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
US7589181B2 (en) | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
US8470315B2 (en) | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
US20070298443A1 (en) * | 2004-06-04 | 2007-12-27 | Yiyou Chen | Screening Method Using Antibody Heavy Chains |
US20090104119A1 (en) * | 2004-08-25 | 2009-04-23 | Majoros Istvan J | Dendrimer Based Compositions And Methods Of Using The Same |
DK1838736T3 (da) | 2005-01-05 | 2013-06-03 | Biogen Idec Inc | Cripto-bindende molekyler |
US20070041934A1 (en) * | 2005-08-12 | 2007-02-22 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
JP2009541333A (ja) * | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
EP2049151A4 (de) * | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | Verfahren und zusammensetzungen zur behandlung von krebs |
US20090088376A1 (en) * | 2007-04-19 | 2009-04-02 | The Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
WO2009026540A1 (en) | 2007-08-22 | 2009-02-26 | Colorado School Of Mines | Lanthanide nanoparticle conjugates and uses thereof |
EP2205271B1 (de) * | 2007-10-08 | 2014-05-21 | Quintessence Biosciences, Inc. | Zusammensetzungen und verfahren für therapien auf ribonukleasebasis |
WO2009151687A2 (en) | 2008-03-12 | 2009-12-17 | The Regents Of The University Of Michigan | Dendrimer conjugates |
US8968705B2 (en) | 2008-08-22 | 2015-03-03 | Colorado School Of Mines | Gold/lanthanide nanoparticle conjugates and uses thereof |
WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
WO2010039985A1 (en) | 2008-10-01 | 2010-04-08 | Quintessence Biosciences, Inc. | Therapeutic Ribonucleases |
WO2010042823A1 (en) | 2008-10-09 | 2010-04-15 | Northeastern Universtiy | Multifunctional self-assembling polymeric nanosystems |
WO2010054321A2 (en) | 2008-11-07 | 2010-05-14 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
AU2010318637A1 (en) | 2009-10-13 | 2012-05-31 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
WO2011059586A2 (en) | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
US20110201076A1 (en) | 2010-01-22 | 2011-08-18 | Colorado School Of Mines | Harvesting micro algae |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
TWI497073B (zh) * | 2011-08-11 | 2015-08-21 | Atomic Energy Council | 96孔盤格式運用於放射免疫分析之方法 |
US9402911B2 (en) | 2011-12-08 | 2016-08-02 | The Regents Of The University Of Michigan | Multifunctional small molecules |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361544A (en) * | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4565687A (en) * | 1981-11-16 | 1986-01-21 | The Reagents Of The University Of Michigan | Monoclonal antibodies specific for the unbound β subunit of human chorionic gonadotropin |
US4522918A (en) * | 1981-12-15 | 1985-06-11 | Jeffery Schlom | Process for producing monoclonal antibodies reactive with human breast cancer |
US4612282A (en) * | 1981-12-15 | 1986-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibodies reactive with human breast cancer |
US4634586A (en) * | 1984-05-21 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reagent and method for radioimaging leukocytes |
-
1988
- 1988-06-07 AT AT88907519T patent/ATE162308T1/de not_active IP Right Cessation
- 1988-06-07 DE DE3856108T patent/DE3856108T2/de not_active Expired - Lifetime
- 1988-06-07 WO PCT/US1988/001941 patent/WO1989000692A1/en active IP Right Grant
- 1988-06-07 JP JP63506468A patent/JP3095752B2/ja not_active Expired - Lifetime
- 1988-06-07 EP EP88907519A patent/EP0394277B1/de not_active Expired - Lifetime
- 1988-06-21 IL IL86809A patent/IL86809A/xx not_active IP Right Cessation
- 1988-07-13 CA CA000571894A patent/CA1339980C/en not_active Expired - Lifetime
-
1990
- 1990-07-02 US US07/547,336 patent/US5512443A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5512443A (en) | 1996-04-30 |
DE3856108T2 (de) | 1998-07-09 |
EP0394277B1 (de) | 1998-01-14 |
IL86809A (en) | 1993-07-08 |
JPH03504436A (ja) | 1991-10-03 |
EP0394277A1 (de) | 1990-10-31 |
WO1989000692A1 (en) | 1989-01-26 |
EP0394277A4 (en) | 1991-01-16 |
JP3095752B2 (ja) | 2000-10-10 |
CA1339980C (en) | 1998-08-04 |
DE3856108D1 (de) | 1998-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE162308T1 (de) | Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendung | |
DE3070655D1 (en) | Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, method of preparation of this antibody, diagnostic and therapeutic uses, and pharmaceutical compositions comprising this antibody | |
CA2111845A1 (en) | Monoclonal antibodies specific for marrow-derived mesenchymal cells | |
DE3586536T3 (de) | Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin. | |
PH20275A (en) | Hybrid cell line for producing monoclonal antibody to a human t cell antigen, antibody and methods | |
DK0697955T3 (da) | Fremgangsmåde til fremstilling af et legeme med honeycomb-struktur samt et legeme med honeycomb-struktur | |
PT86792A (pt) | Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor | |
DE3070896D1 (en) | Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic compositions comprising it | |
AU5320196A (en) | The gc1q receptor, hiv-1 gp120 region binding thereto, and r elated peptides and targeting antibodies | |
ZA8198B (en) | Hybrid cell line for producing monoclonal antibody to a human monocyte antigen,antibody,and methods | |
ES497424A0 (es) | Un metodo de preparacion de un anticuerpo monoclonal. | |
ATE221122T1 (de) | Monoklonale antikörper, verfahren zu ihrer herstellung sowie ihre verwendung | |
DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
EP0191846A4 (de) | Herstellung monoklonaler anti-idiotyp-antikörper. | |
DE58904746D1 (de) | Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren. | |
DE3467758D1 (de) | 2,6-dioxa-bicyclo-û2,2,2¨-octan-7-yl-acetaldehydes | |
IL73281A0 (en) | Purified antigen isolated from sera of leukemia and lymphoma patients,novel antibodies to said antigen,methods of preparing same and diagnostic and therapeutic methods employing said antibody | |
ATE90793T1 (de) | Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
EELA | Cancelled due to lapse of time |